Prophylactic Salpingectomy for the Prevention of the Ovarian Cancer: Comparison Between Surgical Techniques
Rad_PBS
1 other identifier
interventional
177
1 country
1
Brief Summary
The aim of this RCT of study is to compare the outcomes of the standard salpingectomy (removal of the fallopian tube) with the radical removal of the tube and the mesosalpinx in terms of ovarian reserve.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 9, 2014
CompletedFirst Posted
Study publicly available on registry
March 13, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2015
CompletedApril 21, 2015
April 1, 2015
10 months
March 9, 2014
April 19, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ovarian reserve change
The basal levels of AMH, FSH and estradiol, the antral follicle count (AFC), the ovarian volume, the Vascularization Index (VI), the flow index (FI) and the 'vascular flow index (VFI) in all healthy women over a period of time between the first and fourth day of their menstrual cycle will be assessed.
One, and 3 months after surgery
Secondary Outcomes (5)
Operative times
The same day of surgery
Intraoperative blood loss
two hours after the end of surgery
postoperative hospital stay
The day of patient discharge, everage 4 day after surgery
return to the normal activities
two month after surgery
complication rate
The day of patient discharge, everage 4 day after surgery
Study Arms (2)
Standard PBS
ACTIVE COMPARATORthe tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
Radical PBS
EXPERIMENTALthe tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
Interventions
the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
Eligibility Criteria
You may qualify if:
- Patients subjected to a laparoscopic surgery for a benign gynecologic disease or who require tubal surgical sterilization, once they have accomplished their reproductive desire, and after the acquisition of a written consent for prophylactic salpingectomy and the ovarian preservation.
- Age between 35 and 50 years
- Regular menstruation with intervals between 22 and 35 days
You may not qualify if:
- Patients with a family history of ovarian cancer and with a known mutation of the BRCA1/2 genes
- Patients with a current or a past history of cancer
- Patients who don't consent to the prophylactic salpingectomy
- Patients subjected to hysterectomy
- Previous adnexal surgery
- PCOS
- Estrogen-progestin therapy in the 2 months prior to the enrollment
- Acute or chronic pelvic inflammatory disorders
- Malignant gynecological neoplasms
- Prior chemotherapy or radiotherapy
- Autoimmune diseases, chronic, metabolic, endocrine and systemic disorders, including hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease
- Hypogonadotropic hypogonadism
- Taking medications that can cause menstrual irregularities
- Other clinical conditions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chair of Obstetrics and Gynecology - University division - UMG
Catanzaro, CZ, 88100, Italy
Related Publications (2)
Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, D'Alessandro P, Zullo F. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol. 2013 Jun;129(3):448-51. doi: 10.1016/j.ygyno.2013.03.023. Epub 2013 Apr 2.
PMID: 23558052BACKGROUNDVenturella R, Morelli M, Lico D, Di Cello A, Rocca M, Sacchinelli A, Mocciaro R, D'Alessandro P, Maiorana A, Gizzo S, Zullo F. Wide excision of soft tissues adjacent to the ovary and fallopian tube does not impair the ovarian reserve in women undergoing prophylactic bilateral salpingectomy: results from a randomized, controlled trial. Fertil Steril. 2015 Nov;104(5):1332-9. doi: 10.1016/j.fertnstert.2015.08.004. Epub 2015 Aug 31.
PMID: 26335129DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fulvio Zullo
Magna Graecia University of Catanzaro
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Full Professor Obstetric Gynecology
Study Record Dates
First Submitted
March 9, 2014
First Posted
March 13, 2014
Study Start
March 1, 2014
Primary Completion
January 1, 2015
Study Completion
April 1, 2015
Last Updated
April 21, 2015
Record last verified: 2015-04